Cordis US
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Cordis US sits in the top decile of US sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count).
Cordis US: 19 sponsored US clinical trials, 1 recruiting.
Cordis US sponsors 19 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 17 completed. 10 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is PAD, with 1 trials.
Top-decile sponsor footprint
Cordis US ranks in the top decile of sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
17 of 18 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (94.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
19 total, page 1 of 1
Mobilization and Outcomes After Venous Closure
NCT07246902
Evaluation of Safety and Efficacy of the Mynx Control Venous Vascular Closure Device 6F-12F vs Manual Compression
NCT05554471
A Multicenter, Open Label, Prospective, Non-randomized Study of the InCraft® Stent Graft System in Subjects With Abdominal Aortic Aneurysms (INSPIRATION)
NCT01664078
Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System
NCT01355406
S.M.A.R.T.® Nitinol Self-Expandable Stent in the Treatment of Obstructive Superficial Femoral Artery Disease
NCT00739102
Safety and Effectiveness Study of the Ensure Medical Vascular Closure Device
NCT00345631
SAPPHIRE Worldwide: Stenting and Angioplasty With Protection in Patients At High-Risk for Endarterectomy
NCT00403078
Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)
NCT00165035
An Observational Registry Using Drug Eluting Stents (DES) in Patients in a Real-World Setting (DEScover Registry).
NCT00489320
Carotid Artery Stenting With Emboli Protection Surveillance-Post-Marketing Study (CASES-PMS)
NCT00231231
NEXUS Study for the Treatment of de Novo Native Coronary Artery Lesions
NCT00231283
Study of the 4.0mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions
NCT00232752
Study of the 2.25mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions
NCT00232739
Sirolimus-Eluting Stent vs. Intravascular Brachytherapy in In-Stent Restenotic Coronary Artery Lesions(SISR)
NCT00231257
Feasibility Study With the Sirolimus-Eluting BX Velocity Balloon-Expandable Stent in the Treatment of Diabetic Patients With Native Coronary Artery Lesions
NCT00489164
Sirolimus-Eluting BX VELOCITYTM Balloon-Expandable Stent in a Compassionate Use Registry (SECURE)
NCT00231244
Study of the Endovascular QUANTUM LP™ Stent Graft System in Abdominal Aortic Aneurysms (AAA)
NCT00233688
Study of Sirolimus-Coated BX VELOCITY Balloon-Expandable Stent in Treatment of de Novo Native Coronary Artery Lesions (SIRIUS)
NCT00232765
Cordis Bilateral AAA Device Compared to Open Surgical Repair of Abdominal Aortic Aneurysms (ARIBA)
NCT00235118
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 10 |
Where Cordis US enrollment is open (later-stage tilt)
1 recruiting of 19 indexed (5% open); 17 completed (89%).
Phase mix: 10 late (III/IV) vs 2 early (I/II) (later-stage heavy).
Top condition: PAD (1 trial), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Cordis US: open-pipeline peers nationwide
Peers matched on 19 registered trials and 5% open enrollment, not the therapeutic-area sidebar.
Cordis US sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 19 trials (± recruiting share)
- Almirall, S.A. · 19 trials · 5% recruiting
- Bastyr University · 19 trials · 11% recruiting
- Church & Dwight Company · 19 trials · 0% recruiting
- Defense and Veterans Center for Integrative Pain Management · 19 trials · 5% recruiting
Sponsors near 5% open enrollment (± trial volume)
- DePuy Orthopaedics · 5% recruiting · 38 trials
- Impax Laboratories · 5% recruiting · 19 trials
- Kent State University · 5% recruiting · 19 trials
- Omeros Corporation · 5% recruiting · 19 trials
Related
What to do with this Cordis US page
19 registered trials is a research-attention snapshot, not an endorsement of Cordis US or any single study.
- 1 of Cordis US's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- PAD is the condition Cordis US studies most, compare against other sponsors active in the same condition before evaluating a specific study. See PAD trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Cordis US pipeline card: 19 registered trials from official public datasets.Report a data error.